Search Results - "Kramer, Vasko"

Initial results with [¹⁸F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.

Authors: Mori, Yuriko Kramer, Vasko Novruzov, Emil et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. May2024, Vol. 51 Issue 6, p1605-1611. 7p.

Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC.

Authors: Kramer, Vasko Fernández, René Lehnert, Wencke et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2021, Vol. 48 Issue 3, p893-903. 11p. 4 Charts, 2 Graphs.

Pharmacokinetic evaluation of [18F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain.

Authors: Kramer, Vasko Juri, Carlos Riss, Patrick J. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2020, Vol. 47 Issue 8, p1927-1937. 11p. 1 Color Photograph, 2 Charts, 4 Graphs.

Diagnostic accuracy of ¹⁸F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.

Authors: Sprute, Katharina Kramer, Vasko Koerber, Stefan A. et al.

Source: Journal of Nuclear Medicine. Dec2020, Vol. 61 Issue 12, p1-28. 28p.

Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain.

Authors: Kramer, Vasko Dyssegaard, Agnete Flores, Jonathan et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Feb2020, Vol. 47 Issue 2, p355-365. 11p. 1 Diagram, 1 Chart, 4 Graphs.

Direct radiofluorination of [¹⁸F]MH.MZ for 5-HT2A receptor molecular imaging with PET.

Authors: Herth, Matthias M. Kramer, Vasko Gillings, Nic et al.

Source: Journal of Labelled Compounds & Radiopharmaceuticals. Jul2012, Vol. 55 Issue 9, p354-358. 5p.

Structural Combination of Established 5-HT2A Receptor Ligands: New Aspects of the Binding Mode.

Authors: Kramer, Vasko Herth, Matthias M. Santini, Martin A. et al.

Source: Chemical Biology & Drug Design. Oct2010, Vol. 76 Issue 4, p361-366. 6p. 5 Diagrams, 3 Charts, 1 Graph.

Safety and efficacy of [¹⁷⁷Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer.

Authors: Fernández, René Soza-Ried, Cristian Kramer, Vasko et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2026, Vol. 53 Issue 4, p2282-2294. 13p.

The analysis of biodistribution and tumor uptake of [¹⁸F]AlF-FAPI-74 in patients with soft tissue sarcoma and gastro-intestinal tumors compared with [¹⁸F]FDG in a prospective, exploratory study.

Authors: Novruzov, Emil Giesel, Frederik L. Mamlins, Eduards et al.

Source: EJNMMI Reports. 3/6/2026, Vol. 10 Issue 1, p1-14. 14p.

Al[ 18 F]F-NOTA-Octreotide Is Comparable to [ 68 Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population.

Authors: Haeger, Arlette Soza-Ried, Cristian Kramer, Vasko et al.

Source: Cancers. Jan2023, Vol. 15 Issue 2, p439. 11p.

Prodromal manifestations of Parkinson disease in adults with 22q11.2 microdeletion syndrome.

Authors: Repetto, Gabriela Cuiza, Analía Chaná, Pedro et al.

Source: Contacto Científico Clínica Alemana. 2019, Vol. 9 Issue 3, p61-61. 1p.

Subjects: PARKINSON'S disease, NEURONS, CLINICAL trials, RAPID eye movement sleep, DOPAMINE

Synthesis and in vitro affinities of various MDL 100907 derivatives as potential ¹⁸F-radioligands for 5-HT2A receptor imaging with PET

Authors: Herth, Matthias M. Kramer, Vasko Piel, Markus et al.

Source: Bioorganic & Medicinal Chemistry. Apr2009, Vol. 17 Issue 8, p2989-3002. 14p.

Biodistribution and dosimetry of [¹⁷⁷Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.

Authors: Ritt, Philipp Fernández, René Soza-Ried, Cristian et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jun2025, Vol. 52 Issue 7, p2431-2443. 13p.

A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry.

Authors: Morgat, Clément Duan, Heying Dalm, Simone et al.

Source: Journal of Nuclear Medicine. Aug2025, Vol. 66 Issue 8, p1160-1167. 8p.

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.

Authors: Ballal, Sanjana Yadav, Madhav Prasad Kramer, Vasko et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2021, Vol. 48 Issue 3, p942-944. 3p. 1 Color Photograph.

A protocol for controlled reactivity shift in the 2,2-difluorovinyl motif used for selective S–¹⁸F and C–¹⁸F bond formation.

Authors: Maqbool, Mudasir Jakobsson, Jimmy Erik Alluri, Santosh Reddy et al.

Source: Communications Chemistry. 4/29/2024, Vol. 7 Issue 1, p1-6. 6p.

Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [ 68 Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [ 68 Ga]Ga-PSMA-11.

Authors: Fernández, René Soza-Ried, Cristian Iagaru, Andrei et al.

Source: Cancers. Jan2024, Vol. 16 Issue 1, p173. 13p.

Expanding the Phenotypic Spectrum of NUS1‐Related Disorders: A Case of Childhood‐Onset Parkinsonism.

Authors: Munoz‐Chesta, Daniela Mendez, Alejandra Hidalgo, Maria et al.

Source: Movement Disorders Clinical Practice. Feb2026, p1. 3p. 1 Illustration.

The promising potential of camelid nanobodies for nuclear medicine.

Authors: Biersack, Hans J. Rojas-Fernandez, Alejandro Ting, Hong-Hoi et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2025, Vol. 52 Issue 8, p2752-2753. 2p.

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [ 18 F]FAPI-74 with [ 18 F]FDG in Patients with PDAC: A Prospective Exploratory Study.

Authors: Novruzov, Emil Giesel, Frederik L. Mori, Yuriko et al.

Source: Cancers. May2023, Vol. 15 Issue 10, p2798. 13p.